Mirum Pharmaceuticals Inc (MIRM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mirum Pharmaceuticals Inc stock (MIRM) is currently trading at $90.17. Mirum Pharmaceuticals Inc PS ratio (Price-to-Sales) is 10.17. Analyst consensus price target for MIRM is $124.64. WallStSmart rates MIRM as Sell.
- MIRM PE ratio analysis and historical PE chart
- MIRM PS ratio (Price-to-Sales) history and trend
- MIRM intrinsic value — DCF, Graham Number, EPV models
- MIRM stock price prediction 2025 2026 2027 2028 2029 2030
- MIRM fair value vs current price
- MIRM insider transactions and insider buying
- Is MIRM undervalued or overvalued?
- Mirum Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- MIRM Piotroski F-Score and Altman Z-Score
- MIRM analyst price target and Smart Rating
Mirum Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Mirum Pharmaceuticals Inc (MIRM) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Mirum Pharmaceuticals Inc (MIRM) Key Strengths (3)
Revenue surging 49.80% year-over-year
105.06% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Mirum Pharmaceuticals Inc (MIRM) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 10.2x annual revenue
Very expensive at 17.1x book value
Supporting Valuation Data
Mirum Pharmaceuticals Inc (MIRM) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 49.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (10.17), Price/Book (17.14) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -8.65%, Operating Margin at -3.07%, Profit Margin at -4.48%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -8.65% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 49.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MIRM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MIRM's Price-to-Sales ratio of 10.17x trades at a deep discount to its historical average of 37.33x (17th percentile). The current valuation is 90% below its historical high of 106.37x set in Apr 2021, and 40% above its historical low of 7.25x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~8.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Mirum Pharmaceuticals Inc (MIRM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Mirum Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 521M with 50% growth year-over-year. The company is currently unprofitable, posting a -4.5% profit margin.
Key Findings
Revenue growing at 50% YoY, reaching 521M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 5M in free cash flow and 6M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -4.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Mirum Pharmaceuticals Inc maintain 50%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Mirum Pharmaceuticals Inc.
Bottom Line
Mirum Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 50% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -4.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Mirum Pharmaceuticals Inc(MIRM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.